8-K ·Filed Mar 26, 2026

NKTX

Nkarta, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001787400-26-000008
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Monitor for future disclosures of actual sales under this ATM program, as equity issuance could pressure the stock price, especially given Nkarta's $151M market cap. The 3% commission structure is standard but adds to issuance costs.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
NKTX ▲ +38.32% at T+60d
SHORT call ✗ call lost -38.32% · α vs SPY -24.37% · entry $2.14 → $2.96
Entry anchored
Mar 25, 03:59 PM ET
via exchange tick
T+1d
-3.74%
call +3.74% · α +2.06%
$2.06
settled 6mo ago
T+5d
+8.41%
call -8.41% · α -6.78%
$2.32
settled 6mo ago
T+20d
+36.45%
call -36.45% · α -25.78%
$2.92
settled 5mo ago
T+60d
+38.32%
call -38.32% · α -24.37%
$2.96
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Nkarta, Inc. announced an at-the-market (ATM) offering program allowing it to sell up to $100 million in common stock through Stifel as sales agent. The company will have full discretion over the timing, pricing, and amount of shares sold, and will pay Stifel a commission of up to 3% of gross proceeds.

Key Facts

  • Nkarta entered into a sales agreement with Stifel for an at-the-market offering of up to $100,000,000 in common stock
  • The offering is discretionary — Nkarta controls timing, volume, and minimum price of sales
  • Stifel will earn a commission of up to 3% of gross proceeds from shares sold
  • The shares will be issued under a Form S-3 registration statement filed the same day
  • No shares have been sold yet; this establishes a potential future equity dilution mechanism

Financial Impact

Up to $100,000,000 in potential equity dilution, with $3,000,000 in total potential commissions (3%)

dilutioncashshares outstanding

Risk Factors

  • Significant dilution risk if the full $100M is issued, especially in a low-price environment
  • Potential for negative market perception of equity financing by a small-cap biotech with no revenue
  • Proceeds may not lead to value-accretive developments, increasing burn without clear milestones

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001787400-26-000008
Document: 0001787400-26-000008-index-headers.html0001787400-26-000008
Document: 0001787400-26-000008-index.html0001787400-26-000008
Document: 0001787400-26-000008.txt0001787400-26-000008
8 reports for NKTX
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+1▲ +23.93%Apr 15, 2026
Filters
Rows
Reports for NKTX — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
8-K
BEARISH ★ 6/10
$2.33 $2.91▼ −24.89%▼ −25.95%$2.58 (−10.52%)
May 12, 2026
20w ago
Press Release
NEUTRAL ★ 4/10
$3.06 $2.76▼ −9.80%▼ −9.19%$2.58 (−15.85%)
Apr 15, 2026
24w ago
Press Release
BULLISH ★ 7/10
$2.80 $3.06▲ +9.29%▲ +3.47%$2.58 (−8.04%)
Apr 6, 2026
25w ago
EFFECT
BEARISH ★ 7/10
$2.36 $3.02▼ −27.97%▼ −18.98%$2.58 (−9.11%)
Mar 26, 2026
27w ago
8-K
BEARISH ★ 6/10
$2.14 $2.92▼ −36.45%▼ −25.78%$2.58 (−20.33%)
Mar 25, 2026
27w ago
S-3
BEARISH ★ 7/10
$2.14 $2.92▼ −36.45%▼ −25.78%$2.58 (−20.33%)
Mar 25, 2026
27w ago
Press Release
NEUTRAL ★ 5/10
$2.14 $2.92▲ +36.45%▲ +25.78%$2.58 (+20.33%)
Feb 28, 2026
30w ago
Institutional Cluster
BULLISH ★ 6/10
$2.70 $2.00▼ −25.93%▼ −17.99%$2.58 (−4.63%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (65h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access